Mesenchymal stem cell injections for the treatment of perianal crohn's disease: What we have accomplished and what we still need to do

Amy Lightner, William Alvis Faubion

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Perianal Crohn's disease [CD] is found in a quarter of patients with CD and remains notoriously difficult to treat. Several medical and surgical therapies are available. However, none is particularly effective nor reliably provides sustained remission. In addition, surgical intervention is complicated by poor healing and the potential for incontinence. Mesenchymal stem cell-based therapies provide a promising treatment alternative for perianal CD, with demonstrated safety, improved efficacy, and a decreased side effect profile. Several phase I, II, and now III randomised controlled trials have now reported safety and efficacy in treating perianal CD. The aim of this review is to discusses the outcomes of conventional treatment approaches, outcomes of mesenchymal stem cell therapies, considerations specific to stem cell-based therapies, and future directions for research.

Original languageEnglish (US)
Pages (from-to)1267-1276
Number of pages10
JournalJournal of Crohn's and Colitis
Volume11
Issue number10
DOIs
StatePublished - Oct 1 2017

Fingerprint

Mesenchymal Stromal Cells
Crohn Disease
Cell- and Tissue-Based Therapy
Injections
Safety
Therapeutics
Stem Cells
Randomized Controlled Trials
Research

Keywords

  • Crohn's disease
  • Perianal fistula
  • Stem cells

ASJC Scopus subject areas

  • Gastroenterology

Cite this

@article{68c3d3650db64a398388be6c9184cb43,
title = "Mesenchymal stem cell injections for the treatment of perianal crohn's disease: What we have accomplished and what we still need to do",
abstract = "Perianal Crohn's disease [CD] is found in a quarter of patients with CD and remains notoriously difficult to treat. Several medical and surgical therapies are available. However, none is particularly effective nor reliably provides sustained remission. In addition, surgical intervention is complicated by poor healing and the potential for incontinence. Mesenchymal stem cell-based therapies provide a promising treatment alternative for perianal CD, with demonstrated safety, improved efficacy, and a decreased side effect profile. Several phase I, II, and now III randomised controlled trials have now reported safety and efficacy in treating perianal CD. The aim of this review is to discusses the outcomes of conventional treatment approaches, outcomes of mesenchymal stem cell therapies, considerations specific to stem cell-based therapies, and future directions for research.",
keywords = "Crohn's disease, Perianal fistula, Stem cells",
author = "Amy Lightner and Faubion, {William Alvis}",
year = "2017",
month = "10",
day = "1",
doi = "10.1093/ecco-jcc/jjx046",
language = "English (US)",
volume = "11",
pages = "1267--1276",
journal = "Journal of Crohn's and Colitis",
issn = "1873-9946",
publisher = "Elsevier",
number = "10",

}

TY - JOUR

T1 - Mesenchymal stem cell injections for the treatment of perianal crohn's disease

T2 - What we have accomplished and what we still need to do

AU - Lightner, Amy

AU - Faubion, William Alvis

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Perianal Crohn's disease [CD] is found in a quarter of patients with CD and remains notoriously difficult to treat. Several medical and surgical therapies are available. However, none is particularly effective nor reliably provides sustained remission. In addition, surgical intervention is complicated by poor healing and the potential for incontinence. Mesenchymal stem cell-based therapies provide a promising treatment alternative for perianal CD, with demonstrated safety, improved efficacy, and a decreased side effect profile. Several phase I, II, and now III randomised controlled trials have now reported safety and efficacy in treating perianal CD. The aim of this review is to discusses the outcomes of conventional treatment approaches, outcomes of mesenchymal stem cell therapies, considerations specific to stem cell-based therapies, and future directions for research.

AB - Perianal Crohn's disease [CD] is found in a quarter of patients with CD and remains notoriously difficult to treat. Several medical and surgical therapies are available. However, none is particularly effective nor reliably provides sustained remission. In addition, surgical intervention is complicated by poor healing and the potential for incontinence. Mesenchymal stem cell-based therapies provide a promising treatment alternative for perianal CD, with demonstrated safety, improved efficacy, and a decreased side effect profile. Several phase I, II, and now III randomised controlled trials have now reported safety and efficacy in treating perianal CD. The aim of this review is to discusses the outcomes of conventional treatment approaches, outcomes of mesenchymal stem cell therapies, considerations specific to stem cell-based therapies, and future directions for research.

KW - Crohn's disease

KW - Perianal fistula

KW - Stem cells

UR - http://www.scopus.com/inward/record.url?scp=85027834304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027834304&partnerID=8YFLogxK

U2 - 10.1093/ecco-jcc/jjx046

DO - 10.1093/ecco-jcc/jjx046

M3 - Review article

C2 - 28387832

AN - SCOPUS:85027834304

VL - 11

SP - 1267

EP - 1276

JO - Journal of Crohn's and Colitis

JF - Journal of Crohn's and Colitis

SN - 1873-9946

IS - 10

ER -